

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**20 January 2024 :: Issue 734**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

## ***Milestones, Perspectives***



### **WHO – 154th session of the Executive Board**

The 154th session of the Executive Board takes place on **22–27 January 2024**. Proceedings will be webcast from [this page](#).

*Main Documents page:* [https://apps.who.int/gb/e/e\\_eb154.html](https://apps.who.int/gb/e/e_eb154.html)

#### **Selected Documents**

##### **EB154/1**

Provisional agenda

##### **EB154/1 (annotated)**

Provisional agenda (annotated)

##### **EB154/9**

Immunization Agenda 2030

Progress towards global immunization goals and implementation of the Immunization Agenda 2030

##### **EB154/14**

WHO's work in health emergencies

Public health emergencies: preparedness and response

##### **EB154/15**

WHO's work in health emergencies

Strengthening the global architecture for health emergency preparedness, prevention and response and resilience

##### **EB154/16**

Implementation of resolution WHA75.11 (2022)

##### **EB154/18**

Poliomyelitis

Poliomyelitis eradication

##### **EB154/19**

Poliomyelitis

Polio transition planning and polio post-certification

##### **EB154/20**

Smallpox eradication: destruction of variola virus stocks



### **EB154/9 Immunization Agenda 2030**

*Progress towards global immunization goals and implementation of the Immunization Agenda 2030*

Report by the Director-General

*[Excerpt; Selected Annexes]*

*...CONCLUSIONS AND NEXT STEPS*

30. The COVID-19 pandemic and a wide range of other environmental and geopolitical challenges have had a highly damaging impact on immunization. Millions of additional young children (and adolescents and adults) are now at risk of life-threatening vaccine-preventable diseases.

31. In 2022, declining global coverage of key indicators, such as DTP3, was halted and reversed, almost returning to levels seen in baseline year 2019.

32. However, recovery has been very uneven across countries, with low-income countries in particular yet to see significant recovery.

33. Within countries, minimal progress has been made in achieving vaccine equity, and gaps between the best-served and least-served districts continue to expand.

34. The Immunization Agenda Technical Progress Report for 2023 includes a shared action agenda, with six short-term priority areas to align the efforts of countries, regions, global partners and other stakeholders, as set forth below.

(1) Catch-up and strengthening: intensify efforts to reach children missed during the pandemic years and strengthen national immunization programmes for all vaccination needs across the life course.

(2) Promoting equity: ensure that catch-up and strengthening activities specifically benefit communities that are currently most left out. EB154/9

(3) Regaining control of measles: enhance measles outbreak responses and intensify prevention, especially within the context of sustainable strengthened national immunization programmes.

(4) Making the case for investment and integration into primary health care: strengthen advocacy at national, regional and global levels for increased investment in immunization, integrated into primary health care and as part of systems for health.

(5) Accelerating new vaccine introduction: promote implementation of vaccines recommended by WHO where they have yet to be introduced.

(6) Advancing vaccination in adolescence: accelerate introduction of human papillomavirus vaccination where it is not yet in national programmes, and increase coverage where it has already been introduced.

35. Refinement of the Immunization Agenda 2030 operational model will continue to shift the focus to the regional level, to facilitate coordinated and tailored support to countries based on their local contexts and needs.

36. In-depth reviews led by the Immunization Agenda 2030 working groups and other activities will collate evidence in priority areas and generate recommendations for global partners and other stakeholders.

#### *ACTION BY THE EXECUTIVE BOARD*

37. The Board is invited to note the report. It is further invited to provide comments and guidance in respect of the questions set out below.

- What actions can global partners take to support countries to accelerate progress in the six priority areas highlighted above (paragraph 34 above)?
- How can countries strengthen their political and financial commitments to immunization within integrated primary health care systems, which is a key enabler of universal health coverage, improved population health and pandemic preparedness?

## ANNEX 2

STRATEGIC PRIORITY (SP) PROGRAMME PERFORMANCE INDICATORS,  
BASELINE AND 2022 DATA<sup>a</sup>

Strategic Priority	Indicator	2022 data <i>Unless otherwise noted, 2021 is indicator baseline</i>
<b>1 Immunization Programmes for Primary Health Care and Universal Health Coverage</b>	1.1 Proportion of countries with evidence of adopted mechanism for monitoring, evaluation and action at national and subnational levels	Data forthcoming in 2023
	1.2 Density of physicians, nurses and midwives per 10 000 population <sup>b</sup>	<b>53.7</b> health workers per 10 000 population <sup>c</sup> (Physicians: 16.9; nurses/midwives: 36.9) <i>2019 baseline: 56.4 (17.4 physicians and 39 nurses/midwives)</i>
	1.3 Proportion of countries with on-time reporting from 90% of districts for suspected cases of all priority VPDs included in nationwide surveillance <sup>b</sup>	<b>38%</b> (9 out of 24 pilot countries reported $\geq 90\%$ timely reporting from $\geq 90\%$ of districts or other administrative levels)
	1.4 Proportion of time with full availability of DTP and MCV at service delivery level <sup>b</sup>	<b>35%</b> (67 out of 194 countries) <sup>d</sup>
	1.6 Proportion of countries with at least one documented (with reporting form and/or line-listed) individual serious adverse event following immunization (AEFI) case safety report per million total population	<b>47%</b> (92 out of 194 countries) <i>2019 baseline: 28% (54 out of 194)</i>
<b>2 Commitment &amp; Demand</b>	2.1 Proportion of countries with legislation in place that is supportive of immunization as a public good <sup>b</sup>	<b>59%</b> (115 out of 194 countries)
	2.2 Proportion of countries that have implemented behavioural or social strategies (i.e., demand generation strategies) to address under-vaccination <sup>b</sup>	<b>45%</b> (87 out of 194 countries)
<b>3 Coverage &amp; Equity</b>	3.2 DTP3, MCV1, and MCV2 coverage in the 20% of districts with lowest coverage (mean across countries)	<b>69% DTP3, 66% MCV1, 57% MCV2</b> <i>2019 baseline: 74% DTP3, 72% MCV1, 64% MCV2</i>
<b>4 Life Course &amp; Integration</b>	4.1 Breadth of protection (mean coverage for all WHO-recommended vaccine antigens)	<b>72%</b> <i>2019 baseline: 71%</i>
<b>5 Outbreaks &amp; Emergencies</b>	5.1 Proportion of polio, measles, meningococcus, yellow fever, cholera, and Ebola outbreaks with timely detection and response	<b>18%</b> (7 out of 40 outbreaks; excluding polio) <i>average 2018–2020 baseline: 25%</i>
<b>6 Supply &amp; Sustainability</b>	6.1 Health of vaccine markets, disaggregated by vaccine antigens and country typology	Data forthcoming in 2023
	6.2 Proportion of countries whose domestic government and donor expenditure on primary health care increased or remained stable	<b>83%</b> (20 out of 24 countries, 2019 to 2020) <i>2018–2019 baseline: 75% (18 out of 24)</i>
	6.3 Proportion of low- and middle-income countries whose share of national immunization schedule vaccine expenditure funded by domestic government resources increased or remained stable <sup>e</sup>	<b>61%</b> (34 out of 56 countries, 2021 to 2022) <i>2018–2019 baseline: 68% (38 out of 56)</i>


7 Research & Innovation	7.1 Proportion of countries with an immunization research agenda <sup>b</sup>	13% (26 out of 194 countries)
	7.2 Progress towards global research and development targets	Data forthcoming in 2024

<sup>a</sup> Table only includes strategic priority objectives for which global indicators have been specified; no global indicators have been specified for strategic priority objective 1.5 or 3.1.

<sup>b</sup> Indicators based on questions from the new electronic WHO/UNICEF Joint Reporting Form on Immunization (eJRF) piloted in 2021. Data have limitations due to novelty of the indicators and ability of countries to report on them. Questions will be revised in the light of lessons learned during piloting.

<sup>c</sup> 2020 data used because 2022 data are not yet available.

<sup>d</sup> Reported at the district level; further discussions will be held to refine the indicator.



.....  
.....

## [Amidst Ongoing Global Crises, Gates Foundation Announces Largest Budget Ever: \\$8.6 Billion in 2024 to Save and Improve Lives](#)

*Increased funding includes support for health innovations that could save millions more lives by 2030*

DAVOS, SWITZERLAND (January 15) – The Bill & Melinda Gates Foundation today announced its largest annual budget to date as it works toward the goal of a healthier, more prosperous world for all. With global health budgets in decline overall, a portion of **the additional funding will go toward advancing global health innovations that will save and improve the lives of some of the world’s most vulnerable people**, including newborn babies and pregnant mothers living in low-income communities.

The foundation’s \$8.6 billion 2024 budget was formally approved by its board of trustees on January 13. **The budget, which represents an increase of 4% over last year and is a \$2 billion**

**increase over the 2021 budget**, comes as global contributions to health in the lowest-income countries are stalling. While overall aid spending has leveled off, sub-Saharan African countries saw a nearly 8% decline in aid in 2022, even as they face growing needs and shrinking budgets due to debt and other financial pressures. The foundation has committed to increasing its annual spending to \$9 billion by 2026...

Despite the phenomenal progress, millions of children in poor countries still die before their fifth birthday of preventable or treatable diseases, and nearly 300,000 women die in childbirth while the tools exist to prevent their deaths. Ninety percent of the 340,000 women who die every year of cervical cancer live in low- and middle-income countries, even though there's now a highly effective one-dose vaccine that can protect them against it...

To emphasize that **many solutions are simple, portable, and already close at hand**, Gates and other foundation leaders will carry backpacks in Davos emblazoned with "The Future of Health" and filled with examples of products that could save millions of lives. They include:

- A package of tools that can save 65,000 women by 2030 from dying of postpartum hemorrhage (PPH). PPH is the biggest cause of maternal death worldwide. The package includes a simple and inexpensive drape to better measure blood loss. When paired with interventions in a trial, these tools decreased cases of severe bleeding by 60%.
- **A one-dose HPV vaccine that helps protect against one of the most common cancers among women worldwide.** Millions of girls in low- and middle-income countries haven't received HPV vaccines, while most girls in high-income countries have. As much as 90% of cervical cancer deaths are in these countries. With a one-dose HPV vaccine, the barriers to vaccination are much lower, and efficacy remains high and lasting. Modeling estimates that more than 110 million cases of cervical cancer can be averted as the one-dose regimen is rolled out, in part through Gavi.
- An AI-enabled ultrasound that uses AI algorithms to identify obstetric risk in pregnancy. This tool can save 390,000 infant lives by 2030 by helping health workers identify high-risk pregnancies in low-resource settings.
- **Vaccine microneedle array patches that can deliver vaccines through the skin** without traditional needles, a complex cold chain, or a highly trained health worker to administer them. Early trials show these patches deliver the measles-rubella vaccine as safely and effectively as syringes and produce a similar immune response. This can help protect the hardest-to-reach children.
- A stack of test strips that reduce production and shipping costs compared to existing cassette tests. These **diagnostic test strips can be made in the billions and shipped inexpensively, allowing for faster response in the event of an outbreak.** They can also increase the number of tests available for diagnosing malaria, of which two-thirds of cases go undiagnosed.
- Multiple micronutrient supplements that restore a pregnant woman's nutrient stores that she transfers to her baby. Studies show the supplements resulted in a reduced risk of low birth weight (12%) and a reduced risk of preterm birth (8%), and even better results among anemic and underweight women. These supplements, which are available now, could prevent 425,000 stillbirths.

"The Gates Foundation measures impact in terms of lives saved and opportunities provided to the poorest," said Gates Foundation CEO Mark Suzman. "This new high-water mark for our budget will further our mission to help create a world where everyone has the opportunity to live a healthy, productive life."...



## World Economic Forum

### [New Global Alliance for Women's Health Could Help Boost Global Economy by \\$1 Trillion Annually by 2040](#)

- A new World Economic Forum report finds that closing the health gap would improve women's health and enable them to participate more actively in the workforce, and lead to a 1.7% increase in per capita GDP.
- 42 organizations are currently supporting the Forum's new Global Alliance for Women's Health, with \$55 million pledged to improve women's health outcomes worldwide.
- Read the full report [here](#). Learn more about the Global Alliance for Women's Health [here](#).

Davos-Klosters, Switzerland, 17 January 2024 – A new World Economic Forum report released today shows that closing the women's health gap would allow more women to live healthier, higher-quality lives, and provide an unprecedented boost to the global economy.

***Closing the Women's Health Gap: A \$1 Trillion Opportunity to Improve Lives and Economies***, developed in collaboration with the McKinsey Health Institute, analyses the health conditions that uniquely or disproportionately affect women and quantifies the health gap today and the potential economic boon of bridging it tomorrow. Addressing shortcomings – which limit the ability of many women to engage in the workforce and earn a living for themselves and their families – could reduce the time women spend in poor health by almost two-thirds, improve the health outcomes and daily lives of over 3.9 billion people, and add \$1 trillion to the economy annually by 2040.

"Our analysis demonstrates that addressing the women's health gap and investing in women's health must be a priority for every country," said Shyam Bishen, Head of the Centre for Health and Healthcare at the World Economic Forum. "Beyond improving women's quality of life, ensuring women have access to innovations in healthcare is one of the best investments that countries can make for their societies and their economies."

Critically, better health is correlated with economic prosperity. **According to the report, women on average spend 25% more of their lives in poor health than men.** Closing the health gap facing women globally could lead to a 1.7% increase in per capita GDP, with every \$1 invested in these efforts potentially unlocking \$3 in economic growth. It urges for greater access to gender-specific care and calls on industry leaders to create new financing models and innovative business policies, with broad multi-sector collaboration highlighted as a crucial step towards achieving these goals...

In response to the report findings, and to bridge the women's health gap, **the World Economic Forum has launched the Global Alliance for Women's Health, a multi-sector global platform that is centred on evidence** that investing in women's health would not only improve billions of individual lives, but also provide a revolutionary economic boon for societies and economies as a whole.

**42 organizations have expressed interest in joining the alliance**, including government leaders and representatives from the private sector, entertainment industry and philanthropic space. Together they will pledge new commitments to advance the alliance's priorities across three pillars: financing, science and innovation, and agenda-setting. **Key partners have already announced \$55 million in pledges to improve women's health outcomes and shape a new future for women's health across the world...**



## ***Featured Analysis***

### **Center for Global Development**

#### **Vaccination Data Is Becoming Systematically Biased**

January 09, 2024

Brian Webster et al.

Child vaccination is one of the most powerful and cost-effective tools to save lives. But just how good is the data that we're using to track progress on this life-saving intervention? In this piece, we examine trends in the quality of government-produced vaccination data. Our main message is that rather than obvious improvement, trends are decidedly mixed: the likelihood that WHO and UNICEF find fault with a country's vaccination estimates has been pretty flat over time (see figure 1) and so has the size of the discrepancies between government figures and WHO/UNICEF estimates, in absolute terms (see figure 2).

But in the past, over- and under-estimates tended to cancel out on average. That's no longer true. In the past few decades, countries have become more and more over-optimistic about their vaccination rates. That's especially true in the poorest countries and is not rooted in issues with measuring newly introduced vaccines.

#### ***Where does vaccination data come from?***

With some \$4 billion spent on inoculating children annually, tracking progress on vaccination rates is a key focus of global health initiatives such as Gavi and UNICEF, not to mention a Sustainable Development Goal. A 2014 CGD working group highlighted how efforts by African governments to track vaccination rates are plagued by low state capacity and bad incentives. Despite such evidence, building better national health data systems has not been a priority of the international community and there is little evidence of overall improvement in data quality in recent years.

The numbers we're concerned with here are governments' own estimates of vaccination coverage. Those estimates are reported to the WHO and UNICEF, who publish national and global trends. But the WHO-UNICEF team, known as WUENIC, don't take country numbers at face value. They compare reported vaccination coverage rates to other existing information and adjust for. Luckily for us, WHO and UNICEF have not only collected national vaccination rate data going back to the mid-1990s, but they have also published some details on when and why they have accepted nationally submitted estimates, or have made adjustments. We used this data to examine the frequency, size, and direction of WHO adjustments relative to nationally submitted estimates.

The probability of a discrepancy in vaccination data is falling in the poorest countries, but not in lower-middle income countries.

There are some partial, positive signs on data quality for the poorest countries. On average, the probability that the WHO and UNICEF adjust a low-income country's vaccination data has fallen over time. While the absolute number of self-reported estimates adjusted by the WHO each year has grown as vaccines have been newly introduced, the chance of an adjustment has fallen off the last two decades to just over 50 percent. The majority of estimates from low-income countries are altered, but these adjustments are becoming less frequent.

However, over the same period the opposite trend is observed from lower-middle income countries. Their estimates have become increasingly likely to be adjusted by WHO, with the share of altered estimates rising from 35 percent in 2004 to 49 percent in 2017. While estimates from lower-middle




income countries are revised less frequently than those from the poorest countries, over time the chance of an adjustment has grown.

We note that some of the countries classified today as lower-middle income were designated as low-income in the late 1990s, but have since transitioned. In other words, some countries are “graduating” to a higher-income bracket and becoming more prosperous, but at the same time, the club they have joined has produced worsening quality vaccination data...

**Figure 1. The probability of a discrepancy hasn’t changed much on average**

*Percentage of National Estimates Adjusted by WHO/UNICEF, 1999–2017*



Source: Compiled by authors using WHO/UNICEF WUENIC data. Countries were classified by low-income, lower-middle income, upper-middle income, and high-income country status as defined by the World Bank in 2022–23. Data were downloaded on 9/26/2023. Countries submit national vaccination rates to the WHO/UNICEF, based on administrative and/or survey data, which in turn are examined and either accepted or adjusted by WHO/UNICEF (see here for explanation). Analysis is limited to country-vaccine data in which there are at least two prior years of government produced vaccination rate estimates.

.....  
 .....  
 .....

**Polio – PHEIC**

**[Polio this week as of 17 Jan 2024 - GPEI](#)**

:: On 26 October 2023, the Polio Partners Group (PPG) of the Global Polio Eradication Initiative (GPEI) convened virtually for the twenty-second high-level meeting of polio stakeholders. The meeting was attended by over 50 representatives from core GPEI partners including stakeholders from governments at the ambassadorial, senior official, and technical levels, as well as international

organizations, foundations, and donors. The statement and presentations from the meeting are now available [here](#).

:: The World Health Organization (WHO) is seeking experts to serve as members of the Polio Research Committee (PRC). [This "Call for experts"](#) provides information about the PRC, the expert profiles being sought, the process to express interest, and the process of selection. Application deadline: 2 February 2024. If you have any questions, please e-mail [polioresearch@who.int](mailto:polioresearch@who.int).

***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Afghanistan: seven wild poliovirus type 1 (WPV1)-positive environmental samples
- Pakistan: three WPV1-positive environmental samples
- Chad: one cVDPV2 case
- Côte d'Ivoire: one cVDPV2 case and one positive environmental sample
- DR Congo: four cVDPV1 cases and one cVDPV2 case
- Mozambique: one cVDPV1 case
- Nigeria: six cVDPV2 cases
- South Sudan: one cVDPV2 case
- Zimbabwe: six cVDPV2-positive environmental samples

.....  
.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

**WHO & Regional Offices** [to 20 Jan 2024]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

21 January 2024 Feature story

**[Integration of Traditional, Complementary, and Integrative Medicine \(TCIM\) in the Institutionalization of Evidence-Informed Decision-making](#)**

18 January 2024 News release

**[WHO releases AI ethics and governance guidance for large multi-modal models](#)**

15 January 2024 News release

**[WHO launches appeal for US\\$ 1.5 billion for key emergencies in 2024](#)**

15 January 2024 Joint News Release

**[Preventing famine and deadly disease outbreak in Gaza requires faster, safer aid access and more supply routes](#)**

.....

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**[WHO African Region](#)**

:: 20 January 2024

## [Zambia races to curb fast-spreading cholera outbreak](#)

### **WHO Region of the Americas** PAHO

:: 15 Jan 2024

## [Launch of WHO's Health Emergency Appeal 2024: funding requirements and priorities for the Americas.](#)

January 15, 2024. The World Health Organization (WHO) has officially launched its 2024 Health Emergency Appeal in a high-level livestreamed event on Monday 15 January 2024. The Appeal, which targets over 166 million people who will require health assistance in 2024, aims to enable response to 41 ongoing health crises and deliver critical...

### **WHO South-East Asia Region** SEARO

:: 17 January 2024 News release

## [Maldives, Sri Lanka achieve Hepatitis B control](#)

### **WHO European Region** EURO

*Website not responding at inquiry.*

### **WHO Eastern Mediterranean Region** EMRO

:: 16 January 2024

## [Reaching earthquake-affected people in Herat, Afghanistan, with essential health services](#)

### **WHO Western Pacific Region**

*No new digest content identified.*

.....

## **WHO - Emergency situation reports**

### **COVID-19 epidemiological update – 19 January 2024**

#### Overview

Globally, the number of new cases increased by 4% during the 28-day period of 11 December 2023 to 7 January 2024 as compared to the previous 28-day period, with over 1.1 million new cases. The number of new deaths decreased by 26% as compared to the previous 28-day period, with 8700 new fatalities reported. As of 7 January 2024, over 774 million confirmed cases and over seven million deaths have been reported globally.

During the period from 11 December 2023 to 7 January 2024, COVID-19 new hospitalizations and admissions to an intensive care unit (ICU) both recorded an overall increase of 40% and 13% with over 173 000 and 1900 admissions, respectively.

Globally, JN.1 is currently the most circulating VOI and is now reported by 71 countries, accounting for around 66% of the sequences in week 52 compared to around 25% in week 48. Its parent lineage, BA.2.86, is stable and accounted for 7.8% of sequences in week 52 compared to 7.0% in week 48. The initial risk evaluation for JN.1 was published on 19 December

.....

### **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

.....

## **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 99, No. 03, pp. 11–22 19 January 2024**

<https://iris.who.int/bitstream/handle/10665/375749/WER9903-eng-fre.pdf>

:: Meeting of the Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC), September 2023

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

18 January 2024

### **[Ethics and governance of artificial intelligence for health: Guidance on large multi-modal models](#)**

*Overview*

Artificial Intelligence (AI) refers to the capability of algorithms integrated into systems and tools to learn from data so that they can perform automated tasks without explicit programming of every step by a human. Generative AI is a category of AI techniques in which algorithms are trained on data sets that can be used to generate new content, such as text, images or video. This guidance addresses one type of generative AI, large multi-modal models (LMMs), which can accept one or more type of data input and generate diverse outputs that are not limited to the type of data fed into the algorithm. It has been predicted that LMMs will have wide use and application in health care, scientific research, public health and drug development. LMMs are also known as “general-purpose foundation models”, although it is not yet proven whether LMMs can accomplish a wide range of tasks and purposes.

18 January 2024

### **[Operational framework for monitoring social determinants of health equity](#)**

*Overview*

Social determinants of health – broadly defined as the conditions in which people are born, grow, live, work and age, and people’s access to power, money and resources – have a powerful influence on health inequities. In 2021, the Seventy-fourth World Health Assembly adopted resolution WHA74.16 on addressing social determinants of health, which encouraged Member States to integrate social determinants of health into public policies and programmes and adopt multisectoral approaches. The resolution requested the Director-General to develop an “Operational framework ... for the measurement, assessment and addressing, from a cross-sectorial perspective, of the social determinants of health and health inequities”. This Operational framework for monitoring social determinants of health equity provides countries with critical guidance on monitoring the social determinants of health and actions addressing them, and using data for policy action across sectors to improve health equity. The publication is meant as a resource for national governments and their partners. It was drafted under the guidance of an expert group and with internal contributions across the three levels of WHO, as well as through formal consultation with Member States, and was endorsed at the Seventy-sixth World Health Assembly.

18 January 2024

### **[High-level Ministerial Meeting Sustain, Accelerate and Innovate to end TB in the South-East Asia Region](#)**

16 January 2024

**[Protocol: using data to drive governance](#)**

*Overview*

This document introduces a collaboratively developed study protocol to identify what data and information is currently being collected by governments and how this is used for governance of the private sector in health. As part of inclusive health policy, 'situational awareness' and the generation of intelligence is needed by governments on the private sector in health. To perform specific governance functions, such as contracting, more explicit information on the private sector is required. This study responds to recommendations from the private sector landscaping undertaken as part of the WHO strategy report "Engaging the private health service delivery sector through governance in mixed health systems".

16 January 2024

**[Eliminating malaria in the Greater Mekong subregion by reaching the unreached](#)**

16 January 2024

**[Community deployment of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine...](#)**

16 January 2024

**[Rehabilitation in health financing: opportunities on the way to universal health coverage](#)**

.....  
.....

**USA – HHS, FDA, CDC**

**HHS**

*News*

*No new digest content identified.*

**FDA**

*Press Announcements*

*No new digest content identified.*

**FDA VRBPAC**

*Advisory Committee Calendar*

*No new meetings scheduled.*

**CDC/ACIP [U.S.] [to 20 Jan 2024]**

<http://www.cdc.gov/media/index.html>

*Latest News Releases*

*No new digest content identified.*

**ACIP Meetings**

*Next ACIP Meeting*

February 28-29

**MMWR Weekly**

<https://www.cdc.gov/mmwr/index2023.html>

**January 18, 2024 / No. 2**

[PDF of this issue](#)

[Detecting Mpox Cases Through Wastewater Surveillance — United States, August 2022–May 2023  
Mpox Outbreak — Los Angeles County, California, May 4–August 17, 2023](#)



## Europe

### European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

#### [Human medicines: highlights of 2023](#)

In 2023, EMA recommended 77 medicines for marketing authorisation. Of these, 39 had a new active substance which had never been authorised in the European Union (EU) before.

16 January 2024



### European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

News

#### [RespiCast: the new European Respiratory Diseases Forecasting Hub](#)

News - 15 Jan 2024

#### [Joint ECDC-WHO/Europe mpox \(monkeypox\) surveillance bulletin](#)

Epidemiological update - 15 Jan 2024



### Africa CDC [to 20 Jan 2024]

<http://www.africacdc.org/>

*Press Releases, Statements [Selected]*

#### [Africa CDC 7th Anniversary](#)

*"A journey of Commitment and Action to Safeguard Africa's Health"*

On 31 January, Africa CDC will celebrate its 7th anniversary under the theme "A journey of Commitment and Action to safeguard Africa's health". Established in January 2016 by the 26th Ordinary Assembly of Heads of State and Government and officially launched in January 2017, Africa CDC is guided by the principles of leadership, credibility, ownership, delegated authority, timely dissemination of information and transparency in carrying out its day-to-day activities.



### China CDC

<http://www.chinacdc.cn/en/>

### National Health Commission of the People's Republic of China [to 20 Jan 2024]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [to 20 Jan 2024]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

**China CDC Weekly Reports: Current Volume (6)**

**2024-01-19 / No. 3**

[PDF of this issue](#)

- [Preplanned Studies: HIV Infection and Associated Factors Among Out-of-School MSM Aged 16–24 Years — 6 Cities and Tianjin Municipality, China, 2022–2023](#)
- [Commentary \(Obituary\): Zunyou Wu \(1963–2023\) Chief Epidemiologist, China CDC](#)

.....  
.....

***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

***Organization Announcements***

**Paul G. Allen Frontiers Group** [to 20 Jan 2024]

<https://alleninstitute.org/news-press/>

*News*

*Annual Report*

**[20 Years of Impact | 2023 Annual Report](#)**

01.18.2024

20 years ago, the Allen Institute began with an idea to do science differently, to take on some of the biggest, hardest problems in biology through...

**BMGF - Gates Foundation** [to 20 Jan 2024]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

**[Amidst Ongoing Global Crises, Gates Foundation Announces Largest Budget Ever: \\$8.6 Billion in 2024 to Save and Improve Lives](#)**

*Increased funding includes support for health innovations that could save millions more lives by 2030*

DAVOS, SWITZERLAND (January 15) – The Bill & Melinda Gates Foundation today announced its largest annual budget to date as it works toward the goal of a healthier, more prosperous world for all. With global health budgets in decline overall, a portion of the additional funding will go toward advancing global health innovations that will save and improve the lives of some of the world’s most

vulnerable people, including newborn babies and pregnant mothers living in low-income communities.

The foundation's \$8.6 billion 2024 budget was formally approved by its board of trustees on January 13.

The budget, which represents an increase of 4% over last year and is a \$2 billion increase over the 2021 budget, comes as global contributions to health in the lowest-income countries are stalling. While overall aid spending has leveled off, sub-Saharan African countries saw a nearly 8% decline in aid in 2022, even as they face growing needs and shrinking budgets due to debt and other financial pressures. The foundation has committed to increasing its annual spending to \$9 billion by 2026...

### **Bill & Melinda Gates Medical Research Institute** [to 20 Jan 2024]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*  
*News: Articles and Publications*  
*No new digest content identified.*

### **CARB-X** [to 20 Jan 2024]

<https://carb-x.org/>

*News*

01.18.2024

#### **CARB-X is funding Syntiron to develop a maternal vaccine to prevent neonatal sepsis**

CARB-X is awarding Syntiron US\$1.7 million to develop a maternal vaccine that targets *Escherichia coli* and *Klebsiella pneumoniae*, two bacterial species that cause a large portion of neonatal sepsis infections.

### **CEPI – Coalition for Epidemic Preparedness Innovations** [to 20 Jan 2024]

<http://cepi.net/>

*Latest News*

#### **DISEASE X - What it is, and what it is not**

CEPI looks at what people most want to find out about Disease X.

*Blog* 18 Jan 2024

#### **Scientists explore how chrysalis-based 'living bioreactors' could accelerate new vaccine production**

Scientists in Spain are to investigate whether moth chrysalises infected with an insect virus known as a baculovirus could act as 'living bioreactors' in a new rapid vaccine production technique to help protect people faster from pandemic...

*End Pandemics* 17 Jan 2024

### **CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 20 Jan 2024]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*



**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 20 Jan 2024]

<https://www.darpa.mil/news>

News

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 20 Jan 2024]

<https://dukeghic.org/>

News

*No new digest content identified.*

**EDCTP** [to 20 Jan 2024]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

News

*No new digest content identified.*

**Emory Vaccine Center** [to 20 Jan 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

*No new digest content identified.*

**European Vaccine Initiative** [to 20 Jan 2024]

<http://www.euvaccine.eu/>

Latest News, Events

*No new digest content identified.*

**Evidence Aid** [to 20 Jan 2024]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

Resources [Selected]

[Depression and anxiety among doctors during the Covid-19 pandemic](#)

Added January 17, 2024

[Interventions to reduce the risk of SARS-CoV-2 infection in non-healthcare workplaces](#)

Added January 16, 2024

[Experiences of health care workers during the COVID-19 pandemic](#)

Added January 15, 2024

**Fondation Merieux** [to 20 Jan 2024]

<http://www.fondation-merieux.org/>

News, Events

Partnership

### **The Mérieux Foundation joins the Stop TB Partnership**

January 19, 2024 - Global

The Mérieux Foundation has joined the Stop TB Partnership, an international organization bringing together the parties involved in fighting TB and the communities affected by this disease. The aim is to eradicate TB by 2030 – the objective of the END-TB 2030 strategy.

**Gavi** [to 20 Jan 2024]

<https://www.gavi.org/>

News Releases

*No new digest content identified.*

**GE2P2 Global Foundation** [to 20 Jan 2024]

[www.ge2p2.org](http://www.ge2p2.org)

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – January 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 09 January 2024 – Issue 12](#)

**GHIT Fund** [to 20 Jan 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

*No new digest content identified.*

**Global Fund** [to 20 Jan 2024].

<https://www.theglobalfund.org/en/news/>

News & Stories

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 20 Jan 2024]

<https://www.glopid-r.org/news/>

News

*No new digest content identified.*

**Hilleman Laboratories** [to 20 Jan 2024]

<http://www.hilleman-labs.org/>

News & Insights

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 20 Jan 2024]

<https://www.hhmi.org/news>

Press Room

## **Elizabeth Penniman Named Chief of Communications at HHMI**

Penniman brings more than 25 years of leadership in nonprofit and human health communications.

January 18, 2024

## **Human Immunome Project [nee Human Vaccines Project] [to 20 Jan 2024]**

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

## **IAVI [to 20 Jan 2024]**

<https://www.iavi.org/>

*News, Features*

*No new digest content identified.*

## **INSERM [to 20 Jan 2024]**

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

## **International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

18 January 2024

## **9th ICMRA Teleconference Minutes COVID-19 Real-World Evidence observational studies Working Group**

## **ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 20 Jan 2024]**

<https://www.ich.org/page/press-releases>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

## **ICRC [to 20 Jan 2024]**

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

## **ICRC welcomes the agreement to deliver medication to the hostages and medical facilities in Gaza**

From the onset of the events of 7 October 2023, the International Committee of the Red Cross (ICRC) has been calling for the unconditional release of the hostages as a priority, while also pressing for access to them and the ability to provide medica

18-01-2024 | News release

## **IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*  
*No new digest content identified.*

**IFRC** [to 20 Jan 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*Press release 15/01/2024*

**[Cholera outbreak spirals in Zambia: IFRC launches urgent CHF 4 million appeal](#)**

**Institut Pasteur** [to 20 Jan 2024]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 20 Jan 2024]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*Blogs*

**[Engaging young and early-career scientists in the science-policy interface](#)**

The International Science Council (ISC) and the Global Young Academy (GYA) advocated for a stronger multilateral science-policy interface that meaningfully engages young and early-career scientists in the consultations on the UN Declaration on Future Generations.

18.01.2024

*News*

**[Call for expressions of interest in ISC global science-policy work | deadline: 29 February](#)**

Contribute to critical global science-policy work in the multilateral space by expressing your interest and adding your name to the ISC roster of experts below by 29 February.

16.01.2024

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

*No new digest content identified.*

**IVAC** [to 20 Jan 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 20 Jan 2024]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 20 Jan 2024]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 20 Jan 2024]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Bulgaria*

**[MSF provides medical care to asylum seekers arriving in Harmanli](#)**

Project Update 19 Jan 2024

*Sudan*

**[Restrictions and lack of medicines deprive people in Khartoum state of lifesaving care](#)**

Press Release 18 Jan 2024

*Myanmar*

**[Health workers struggle to respond amid severe restrictions in Rakhine state](#)**

Voices from the Field 16 Jan 2024

*Conflict in Sudan*

**[Severe humanitarian needs after half a million people flee violence in Wad Madani](#)**

Project Update 15 Jan 2024

**National Academy of Medicine** - USA [to 20 Jan 2024]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academy of Sciences** - USA [to 20 Jan 2024]

<https://www.nationalacademies.org/newsroom?>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 20 Jan 2024]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

February 22-23, 2024 (Virtual)

**NIH** [to 20 Jan 2024]

<http://www.nih.gov/>

*News Releases*

Wednesday, January 17, 2024

**[NIH-developed HIV antibodies protect animals in proof-of-concept study](#)**

**PATH** [to 20 Jan 2024]

<https://www.path.org/media-center/>

*Newsroom*

**[PATH congratulates Thailand on granting conditional approval for emergency use to first locally produced COVID-19 vaccine](#)**

January 17, 2024

The NDV-HXP-S COVID-19 vaccine produced by Thailand's Government Pharmaceutical Organization (GPO) has the potential to be an affordable option that advances vaccine supply sustainability and pandemic preparedness.

**Rockefeller Foundation** [to 20 Jan 2024]

<https://www.rockefellerfoundation.org/>

*Press Releases and Speeches*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 20 Jan 2024]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 20 Jan 2024]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

**[UNAIDS launches new approach to ensure the long-term sustainability of the HIV response](#)**

19 January 2024

As countries work to reach the goal of ending AIDS as a public health threat by 2030, planning is urgently needed for sustaining the gains from the HIV response beyond 2030.

With that in mind, UNAIDS has released the "[HIV Response Sustainability Primer](#)" which proposes a new approach to ensure the sustainability of the HIV response. This holistic approach includes programmatic, political, policy-related and financial aspects of the HIV response. The new Primer provides the rationale, the definitions, and an in-depth explanation of this new sustainability approach...

**UNICEF** [to 20 Jan 2024]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Statement* 18 January 2024

**[Statement by UNICEF Deputy Executive Director Ted Chaiban upon conclusion of his visit to the Gaza Strip](#)**

<https://www.unicef.org/press-releases/statement-unicef-deputy-executive-director-ted-chaiban-upon-conclusion-his-visit>

GAZA/ NEW YORK, 18 January 2024 - "I have just finished a three-day visit to the Gaza Strip, where I have been able to coordinate with local and international organizations about the emergency response and take stock of humanitarian operations since the last time I was in the Gaza Strip two months ago. But more than that, I was able to meet with...

Press release 15 January 2024

**[As cholera cases continue to rise in parts of Southern Africa, UNICEF calls for increased focus on children in the cholera response](https://www.unicef.org/press-releases/cholera-cases-continue-rise-parts-southern-africa-unicef-calls-increased-focus)**

<https://www.unicef.org/press-releases/cholera-cases-continue-rise-parts-southern-africa-unicef-calls-increased-focus>

NAIROBI, 15 January 2024 - The cholera epidemic that affected multiple countries in Eastern and Southern Africa in 2023 persists and continues to impact the region, placing additional strain on communities and healthcare facilities. Since 2023, 13 countries in the region have battled one of the worst cholera outbreaks to hit the region in years,...

Press release 15 January 2024

**[96,000 children affected by earthquakes in western Afghanistan in dire need of support this winter, UNICEF warns](https://www.unicef.org/press-releases/96000-children-affected-earthquakes-western-afghanistan-dire-need-support-winter)**

<https://www.unicef.org/press-releases/96000-children-affected-earthquakes-western-afghanistan-dire-need-support-winter>

HERAT, Afghanistan, 15 January 2024 – 100 days after earthquakes struck western Afghanistan, UNICEF is calling for greater support for over 96,000 children affected in the aftermath, as a crippling winter grips the country. Over 1,000 people, most of whom were women and children, lost their lives in Afghanistan’s earthquakes last October . In...

**Unitaid** [to 20 Jan 2024]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 20 Jan 2024]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 20 Jan 2024]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*No new digest content identified.*

**Vaccine Confidence Project** [to 20 Jan 2024]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 20 Jan 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

**[Vaccine Update for Providers](#)**

January 2024

This newsletter is meant to keep you up to date on issues related to vaccines quickly and easily.

**Wellcome Trust** [to 20 Jan 2024]

<https://wellcome.org/>

*News, Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 20 Jan 2024]

<https://www.wistar.org/news/press-releases>

*Press Releases*

January 17, 2024

**[Award-Winning Biotech Training Program to Begin Recruitment with New Employer Partner in Life Sciences](#)**

**World Bank** [to 015 Oct 2022]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

**[Digital Transformation Drives Development in Africa](#)**

*Regional Context:* Over 160 million Africans gained broadband internet access between 2019 and 2022. 115 percent increase in internet users between 2016 and 2021 in Sub-Saharan Africa. 191...

Date: January 18, 2024 Type: Result Brief

**WFPHA: World Federation of Public Health Associations** [to 20 Jan 2024]

<https://www.wfpha.org/>

*No new digest content identified.*

**[World Medical Association \[WMA\]](#)** [to 20 Jan 2024]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

**[Global Collaboration for Ethical Medical Research: WMA, AMA, and PAV Unite in Vatican City](#)**

15 January 2024

The World Medical Association (WMA) is proud to announce the partnership with the American Medical Association (USA) and the Pontifical Academy for Life for the organization of a significant Conference on the Revision of the Declaration of Helsinki. This pivotal event, taking place on 18-19 January at the Old Synod Hall in Vatican City, will focus on medical research and experimentation in resource-poor settings...

**[Declaration of Helsinki – Phase I Public Comment Period](#)**

In order to maximize input by all stakeholders and the public, we are providing two separate public comment periods. A phase 1 public comment period is being held now to address issues from the first few regional meetings, and a phase 2 comment period will follow in the spring when additional topics have been addressed.

*Open Now: Phase 1 Public Comment Period Due: 7 February 2024.*

The workgroup's proposed edits to date are now available for public comment. To submit your or your organization's feedback, download the [phase 1 public comment document](#)



**World Organisation for Animal Health** [to 20 Jan 2024]

<https://www.oie.int/en/>

*Press Releases, Statements*

*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 20 Jan 2024]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 20 Jan 2024]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 20 Jan 2024]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 20 Jan 2024]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 20 Jan 2024]

<https://ifpma.org/>

*Selected Press Releases/Statements*

*No new digest announcements identified*

**International Alliance of Patients' Organizations – IAPO** [to 20 Jan 2024]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

**PhRMA** [to 20 Jan 2024]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*

.....  
.....

## ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

### **AstraZeneca**

*Press Releases - No new digest announcements identified.*

### **Bharat Biotech**

*Press Releases - No new digest announcements identified.*

### **BioCubaFarma – Cuba**

*Últimas Noticias - No new digest announcements identified*

### **Biological E**

*News - Website not responding at inquiry*

### **BioNTech**

*Press Releases - No new digest announcements identified.*

### **Boehringer**

*Press Releases - No new digest announcements identified.*

### **CanSinoBIO**

*News - Website not responding at inquiry*

### **CIGB**

*Latest News - No new digest announcements identified.*

### **Cinnagen**

*Recent News - No new digest announcements identified.*

### **Clover Biopharmaceuticals - China**

*News - No new digest announcements identified.*

### **Curevac [Bayer Ag – Germany]**

*News - No new digest announcements identified*

### **Gamaleya National Center/Sputnik**

*Latest News and Events - No new digest announcements identified*

*<https://sputnikvaccine.com/> - No new digest announcements identified*

### **GSK**

*Press releases for media - No new digest announcements identified*

### **IMBCAMS, China**

*Home - Website not responding at inquiry.*

### **Janssen/JNJ**

*Press Releases - No new digest announcements identified*

**Merck**

News releases - No new digest announcements identified

**Moderna**

Press Releases - No new digest announcements identified

**Nanogen**

News - No new digest announcements identified

**Novartis**

News - No new digest announcements identified.

**Novavax**

Press Releases - No new digest announcements identified

**Pfizer**

Recent Press Releases - No new digest announcements identified.

**R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

**Sanofi Pasteur**

Press Releases - No new digest announcements identified.

**Serum Institute of India**

NEWS & ANNOUNCEMENTS - No new digest announcements identified

**Sinopharm/WIBPBIBP**

News - No new digest announcements identified [English translation function not operating]

**Sinovac**

Press Releases - No new digest announcements identified

2024/01/11

**[SINOVAC Announces Approval of Clinical Trial for Reassortant Hexavalent Rotavirus Vaccine](#)**

...the Reassortant Rotavirus Vaccine, Live, Oral, Hexavalent (Vero Cell) [trial] has been approved for clinical trial by the China National Medical Products Administration (NMPA)...

**SK Biosciences**

Press Releases - No new digest announcements identified.

**Takeda**

Newsroom - No new digest announcements identified.

**Valneva**

Press Releases - No new digest announcements identified.

**Vector State Research Centre of Virology and Biotechnology**

Home - Website not responding [404 error]

## **WestVac Biopharma**

*Media - No new digest announcements identified.*

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

*Website [No News/Announcements page identified]*

.....

.....

### ***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

.....

.....

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

## **AJOB Empirical Bioethics**

Volume 14, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

## **AMA Journal of Ethics**

Volume 26, Number 1: E1-96 Jan 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

### ***Critical Pedagogies in Health Professions Education***

Health professions training is mainly competency driven, with students' and trainees' learning and technical skill development regularly assessed, usually in terms of standardized outcomes. Yet, there are good ethical and clinical questions to ask about competency-based medical education, specifically about how schools' and academic health centers' curricula meaningfully motivate learning and skill development about social privilege, health equity, and structural determinants of patients' health and health outcomes. This theme issue considers whether and to what extent skill development about, for example, the affective features of, say, coming to terms with one's privilege is teachable and assessable in competency-based frameworks, especially when those frameworks have a history of excluding key perspectives. Critical pedagogies investigated herein suggest strategies for interrogating teaching and learning methods and curricular content that are socially, culturally, politically, and historically fraught.

### **American Journal of Human Genetics**

Jan 04, 2024 Volume 111 Issue 1 p1-210

<https://www.cell.com/ajhg/current>

#### **This Month in The Journal**

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Biobanks are becoming increasingly common, and although each has its own goals, strengths, and challenges, the standard recipe is a focus on scientific discovery through genetic data linked to electronic health records (EHRs). In this issue, Wiley et al. describe the development of the Colorado Center for Personalized Medicine Biobank (CCPM Biobank), which is not only designed to advance research but also to directly impact patient care. A few key elements were crucial to achieving these dual aims.

[Reviewed earlier]

### **American Journal of Infection Control**

January 2024 Volume 52 Issue 1 p1-140

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

January 2024 Volume 66 Issue 1 p1-194

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

January 2024 114(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 110 (2024): Issue 1 (Jan 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/1/tpmd.110.issue-1.xml>

[Reviewed earlier]

### **Annals of Internal Medicine**

December 2023 Volume 176, Issue 12

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

### **Artificial Intelligence – An International Journal**

Volume 327 February 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/327/suppl/C>

[Reviewed earlier]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 20 Jan 2024)

[No new digest content identified]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 20 Jan 2024)

[No new digest content identified]

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 20 Jan 2024)

[No new digest content identified]

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 20 Jan 2024)

[\*\*Compliance with research ethics in epidemiological studies targeted to conflict-affected areas in Western Ethiopia: validity of informed consent \(VIC\) by information comprehension and voluntariness \(ICV\)\*\*](#)

Authors: Gemechu Tiruneh, Mekdes Yilma, Bizuneh Wakuma, Eba Abdisa, Lami Bayisa, Michelle Nichols, Anja Bedeker and Nicki Tiffin

Content type: Research 18 January 2024

The conduct of research is critical to advancing human health. However, there are issues of ethical concern specific to the design and conduct of research in conflict settings. Conflict-affected countries often lack strong platform to support technical guidance and monitoring of research ethics, which may lead to the use of divergent ethical standards some of which are poorly elaborated and loosely enforced. Despite the growing concern about ethical issues in research, there is a dearth of information about ethical compliance in conflict areas. Valid and ethically informed decision-making is a premier pact with research participants in settling possible ethical issues before commencing the research, which is ensured by gaining informed consent from prospective participants of the research.

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 20 Jan 2024)

[No new digest content identified]

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 20 Jan 2024)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 20 Jan 2024)

**[Acceptability, cost-effectiveness, and capacity of a facility-based seasonal influenza vaccination among high-risk groups: a study protocol in selected tertiary care hospitals of Bangladesh](#)**

*In Bangladesh, seasonal influenza imposes considerable disease and economic burden, especially for those at high-risk of severe disease. The most successful approach for influenza prevention is the administrat...*

Authors: Md Zakiul Hassan, Md Abdullah Al Jubayer Biswas, Mahbubur Rahman, Homayra Rahman Shoshi, Ashrak Shad Pyash, Md Ariful Islam, Md Azizul Haque, Syeda Rukhshana Parvin, Md Tanvir Hossen, Mofakhar Hussain, Mahmudur Rahman, Tahmina Shirin and Fahmida Chowdhury

Citation: BMC Public Health 2024 24:242

Content type: Study Protocol Published on: 20 January 2024

**[Effective partnership and in-country resource mobilization in Sudan for cVDPV2 outbreak response amid multiple emergencies in 2020–2021](#)**

*During 2020 and immediately prior to the COVID-19 pandemic, Sudan was experiencing multiple emergencies including violence, seasonal flooding, and vector-borne disease outbreaks. After more than ten years sinc...*

Authors: Mohammed Taufiq Mashal, Dalya Eltayeb, Ariel Higgins-Steele, Ismael Suleiman El Sheikh, Ni'ma Saeed Abid, Hemant Shukla, Leonard Machado and Hamid Jafari

Citation: BMC Public Health 2024 24:235

Content type: Research Published on: 19 January 2024

**[Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis](#)**

*Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-lev...*

Authors: Hongru Du, Samee Saiyed and Lauren M. Gardner

Citation: BMC Public Health 2024 24:220

Content type: Research Published on: 18 January 2024

**[Misinformation, knowledge and COVID-19 vaccine acceptance: a cross-sectional study among health care workers and the general population in Kampala, Uganda](#)**

*COVID-19 has greatly affected communities worldwide, more so in low- and middle-income countries. To successfully resolve the COVID-19 pandemic, vaccination coverage of more than 80% is required. However, misi...*

Authors: Maxine Atuheirwe, Richard Otim, Keneth Junior Male, Stella Ahimbisibwe, Joachim Dzidzor Sackey and Obondo James Sande

Citation: BMC Public Health 2024 24:203

Content type: Research Published on: 17 January 2024

**[Equity in vaccine coverage in Uganda from 2000 to 2016: revealing the multifaceted nature of inequity](#)**

*This study analyses vaccine coverage and equity among children under five years of age in Uganda based on the 2016 Uganda Demographic and Health Survey (UDHS) dataset. Understanding equity in vaccine access an...*

Authors: Anthony Ssebagereka, Gatien de Broucker, Elizabeth Ekirapa-Kiracho, Rornald Muhumuza Kananura, Alfred Driwale, Joshua Mak, Aloysius Mutebi and Bryan Nicholas Patenaude

Citation: BMC Public Health 2024 24:185

Content type: Research Published on: 15 January 2024

## **[Between now and later: a mixed methods study of HPV vaccination delay among Chinese caregivers in urban Chengdu, China](#)**

*Adolescent girls in China have a low HPV vaccination rate. Although vaccination is recommended by the Chinese health authorities, the cost is not covered by the national immunisation programme. Vaccination del...*

Authors: Vivian Wan-Cheong Yim, Qianyun Wang, Yifan Li, Chuanyun Qin, Weiming Tang, Shenglan Tang, Mark Jit, Jennifer S. Smith, Heidi J. Larson, Joseph D. Tucker, Jing Li, Leesa Lin and Dan Wu

Citation: BMC Public Health 2024 24:183

Content type: Research Published on: 15 January 2024

### **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 20 Jan 2024)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

February 2024 - Volume 29 - 1

<https://ebm.bmj.com/content/29/1>

[New issue; No digest content identified]

### **BMJ Global Health**

January 2024 - Volume 9 - 1

<https://gh.bmj.com/content/9/1>

[Reviewed earlier]

### **Bulletin of the Atomic Scientists**

January 2024

<https://thebulletin.org/magazine/2024-01/>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 102(1); 2024 Jan 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/451803/>

[New issue; No digest content identified]

### **Cell**

Jan 18, 2024 Volume 187 Issue 2 p217-510

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

### **Child Care, Health and Development**

Volume 50, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]



### **Clinical Pharmacology & Therapeutics**

Volume 115, Issue 1 Pages: 1-157 January 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

### **Clinical Therapeutics**

January 2024 Volume 46 Issue 1 p1-84

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 20 Issue 6, December 2023

<https://journals.sagepub.com/toc/ctja/20/6>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 20 Jan 2024]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 135 December 2023

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/135/suppl/C>

[New issue; No digest content identified]

### **The CRISPR Journal**

Volume 6, Issue 6 / December 2023

<https://www.liebertpub.com/toc/crispr/6/6>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 40, Issue 1 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

February 2024 - Volume 37 - Issue 1

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 20 Jan 2024]

[No new digest content identified]

### **Developing World Bioethics**

Volume 23, Issue 4 Pages: 293-377 December 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

*ORIGINAL ARTICLES*

[Reviewed earlier]

### **Development in Practice**

Volume 33, Issue 8, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

### **Development Policy Review**

Volume 42, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 17 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 47, Issue 4 Pages: 847-1173 October 2023

<https://onlinelibrary.wiley.com/toc/14677717/2023/47/4>

[Reviewed earlier]

### **EMBO Reports**

Volume 24 Issue 12 6 December 2023

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 29, Number 12—December 2023

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

## **Epidemics**

Volume 45 December 2023

<https://www.sciencedirect.com/journal/epidemics/vol/45/suppl/C>

[Reviewed earlier]

## **Epidemiology and Infection**

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

## **Ethics & Human Research**

Volume 46, Issue 1 Pages: 1-48 January–February 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

• **Local context and emergency research** • **Participant fraud in online research**  
**Passing demands in autism research :: Women missing in phase I trials**

Articles

Open Access

[\*\*Institutional Review Boards' Assessment of Local Context: A Mixed Methods Study\*\*](#)

Timothy C. Guetterman, Adrienne Haggins, Sacha Montas, Joy Black, Deneil Harney, Michael D. Fetters, Robert Silbergleit, Neal W. Dickert

Pages: 2-13

First Published: 19 January 2024

## **Ethics & International Affairs**

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[New issue; No digest content identified]

## **Ethics, Medicine and Public Health**

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

## **The European Journal of Public Health**

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

[Reviewed earlier]

## **Expert Review of Vaccines**

Vol 22 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

## **Foreign Affairs**

January/February 2024 Volume 103, Number 1  
<https://www.foreignaffairs.com/issues/2023/103/1>  
[Reviewed earlier]

## **Forum for Development Studies**

Volume 50, 2023 - Issue 3  
<http://www.tandfonline.com/toc/sfds20/current>  
[Reviewed earlier]

## **Genetics in Medicines**

Volume 26, Issue 1 January 2024  
<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/12>  
[Reviewed earlier]

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>  
[Accessed 20 Jan 2024]  
[No new digest content identified]

## **Global Health Action**

Volume 17, Issue 1 (2024)  
<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>  
[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 11, No. 6 December 22, 2023  
<http://www.ghspjournal.org/content/current>  
[Reviewed earlier]

## **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>  
[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)  
[Accessed 20 Jan 2024]  
*Book/Printed Material*

### **[Selected issues in biotechnology regulation : Australia, Belgium, Brazil, Canada, China, England, European Union, Germany, India, Japan, Mexico, New Zealand, Singapore, South Africa, South Korea, Taiwan](#)**

"LL File No. 2023-022570." "November 2023." Includes bibliographical references. Description based on online resource; title from PDF cover (Law Library of Congress, viewed Jan. 11, 2024). Contributor: Gilbert, Louis A. - Ahmad, Tariq - Zhang, Laney - Feikert-Ahalt, Clare - Gesley, Jenny - Law Library of Congress (U.S.). Global Legal Research Directorate - Buchanan, Kelly (Kelly S.) - Guerra, Gustavo - Goitom, Hanibal - Soares, Eduardo (Eduardo Da Gama) - Umeda, Sayuri  
Date: 2023

## **Global Public Health**

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

## **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 20 Jan 2024]

[No new digest content identified]

## **Health and Human Rights**

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

***Special Section: Economic Inequality and the Right to Health***

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 18 - Special Issue 4 - October 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

***SPECIAL ISSUE: On the roof top of health policy change***

[Reviewed earlier]

## **Health Policy and Planning**

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

[Reviewed earlier]

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 20 Jan 2024]

[No new digest content identified]

## **Human Gene Therapy**

Volume 34, Issue 23-24 / December 2023

<https://www.liebertpub.com/toc/hum/34/23-24>

[Reviewed earlier]

## **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

### **Immunity**

Dec 12, 2023 Volume 56 Issue 12 p2665-2856

<https://www.cell.com/immunity/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 20 Jan 2024]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 20 Jan 2024]

[No new digest content identified]

### **International Health**

Volume 15, Issue 6, November 2023

<https://academic.oup.com/inthealth/issue/15/6>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-1.xml>

*Table of Contents*

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 10 No. 9 (2023): September 2023

<https://www.ijcmph.com/index.php/ijcmph/issue/view/104>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 16 Issue 3 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3>

*Table of contents*

[Reviewed earlier]

## **JAMA**

January 16, 2024, Vol 331, No. 3, Pages 183-268

<https://jamanetwork.com/journals/jama/currentissue>

*Viewpoint*

### **[Wars in Gaza and Beyond Why Protecting the Sacredness of Health Matters](#)**

Lawrence O. Gostin, JD; Michele B. Goodwin, JD, SJD

JAMA. 2024;331(3):191-192. doi:10.1001/jama.2023.26391

This Viewpoint discusses the importance of safeguarding health access in times armed conflict worldwide and the need to bolster compliance with international humanitarian law.

*Special Communication - AI in Medicine*

### **[Three Epochs of Artificial Intelligence in Health Care](#)**

Michael D. Howell, MD, MPH; Greg S. Corrado, PhD; Karen B. DeSalvo, MD, MPH, MSc

has active quiz has audio

JAMA. 2024;331(3):242-244. doi:10.1001/jama.2023.25057

This Special Communication examines the evolution of artificial intelligence (AI) over the years, and how developments with AI can help decision-makers improve health care while also recognizing its risks.

:: [JAMA Medical News Audio](#): AI and Clinical Practice—AI Gaslighting, AI Hallucinations, and GenAI Potential

:: [Audio](#): How Artificial Intelligence Has Evolved and the Implications for Health Care

## **JAMA Health Forum**

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

## **JAMA Pediatrics**

January 2024, Vol 5, No. 1

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

## **JBIE Evidence Synthesis**

December 2023 - Volume 21 - Issue 12

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

## **Journal of Adolescent Health**

January 2024 Volume 74 Issue 1 p1-212

<https://www.jahonline.org/current>

[Reviewed earlier]

## **Journal of Artificial Intelligence Research**

Vol. 78 (2023)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

### **Journal of Community Health**

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

### **Journal of Development Economics**

Volume 166 January 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/166/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

January 2024 - Volume 78 - 1

<https://jech.bmj.com/content/78/1>

[Reviewed earlier]

### **Journal of Evidence-Based Medicine**

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

### **Journal of Global Ethics**

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[New issue; No digest content identified]

### **Journal of Health Care for the Poor and Underserved (JHCPU)**



Volume 34, Number 4, November 2023

<https://muse.jhu.edu/issue/51329>

*Table of Contents*

[Reviewed earlier]

### **Journal of Immigrant and Minority Health**

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

### **Journal of Immigrant & Refugee Studies**

Volume 21, 2023 \_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

***Towards a New Migration and Asylum Research Agenda for the Americas***

### **Journal of Infectious Diseases**

Volume 228, Issue 12, 15 December 2023

<https://academic.oup.com/jid/issue/228/12>

[New issue; No digest content identified]

### **Journal of International Development**

Volume 36, Issue 1 Pages: 1-772 January 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

*REVIEW ARTICLE*

Open Access

**[International development project success: A literature review](#)**

Nur Chasanah, Indra Gunawan, Bassam Baroudi

Pages: 146-171

First Published: 05 July 2023

### **Journal of Medical Ethics**

January 2024 - Volume 50 - 1

<http://jme.bmj.com/content/current>

[Reviewed earlier]

### **Journal of Patient-Centered Research and Reviews**

Volume 10, Issue 4 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

### **The Journal of Pediatrics**

Volume 264 January 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/264/suppl/C>

[Reviewed earlier]

## **Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

*Review Article*

### **[Predictors for low coverage of uptake of second dose of measles vaccine among children in sub-Saharan Africa, 2023: a systematic review and meta-analysis](#)**

Tamirat Melis, Ayenew Mose, Yohannes Fikadu, Kassahun Haile, Aklilu Habte & Gemechu Jofiro

Article: 2285507

Published online: 07 Dec 2023

*Article*

### **[Impact of pharmacist interventions on immunisation uptake: a systematic review and meta-analysis](#)**

Mohamad Hafiz Abd Rahim, Siti Hajar Mahamad Dom, Mohd Shah Rezan Hamzah, Siti Hawa Azman, Zahirah Zaharuddin & Mathumalar Loganathan Fahrni

Article: 2285955

Published online: 07 Dec 2023

*Article*

### **[A cross-sectional assessment of the effects of select training modalities on vaccine cold chain management](#)**

Aguma Daniel, Joseph Oloro, Innocent Hahirwa, Theogene Rizinde & Marie Françoise Mukanyangezi

Pages: 232-248

Published online: 27 Dec 2023

## **Journal of Public Health Management & Practice**

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

## **Journal of Public Health Policy**

Volume 44, issue 4, December 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-4>

[New issue; No digest content identified]

## **Journal of the Royal Society – Interface**

January 2024 Volume 21 Issue 210

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

## **Journal of Travel Medicine**

Volume 30, Issue 8, December 2023

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

## **Journal of Virology**

Volume 97 • Number 12 • December 2023

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Jan 20, 2024 Volume 403 Number 10423 p219-324

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

### **The Lancet Child & Adolescent Health**

Jan 2024 Volume 8 Number 1 p1-84

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Jan 2024 Volume 6 Number 1 e1-e86

<https://www.thelancet.com/journals/landig/issue/current>

*Editorial*

#### **[Large language models: a new chapter in digital health](#)**

The Lancet Digital Health

*[Excerpt]*

... Taken together, LLMs will likely affect patients' health in 2024 by providing accurate answers to medical questions, assisting diagnosis and treatment planning, and automating administrative health-care tasks among other applications. As we embark on this new chapter of digital health in 2024, we anticipate larger and externally validated studies, using novel LLMs for broad medical applications. We hope that The Lancet Digital Health will serve as a platform for innovations that we believe should go beyond quality and reliability metrics, placing emphasis on the inclusivity of diverse populations addressing potential limitations and bias associated with LLMs, and assessing their clinical implementation, cost-effectiveness, and ethical application in medical research. Moreover, fostering increased accessibility to open-source code and data, employing collaborative research, and ensuring data privacy and sensitive information protection are essential considerations for appropriate use of LLMs in health care.

*Viewpoint*

#### **[Antimicrobial learning systems: an implementation blueprint for artificial intelligence to tackle antimicrobial resistance](#)**

Alex Howard, et al.

### **Lancet Global Health**

Jan 2024 Volume 12 Number 1 e1-e169

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Jan 2024 Volume 24 Number 1 p1-106, e1-e69

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

### **Lancet Public Health**

Jan 2024 Volume 9 Number 1 e1-e67

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

### **Lancet Respiratory Medicine**

Jan 2024 Volume 12 Number 1 p1-88

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 101, Issue 4 Pages: 999-1374 December 2023

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 101, Issue 3 Pages: 637-998 September 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

### **Molecular Therapy**

Jan 03, 2024 Volume 32 Issue 1 p1-260

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

### **Nature**

Volume 625 Issue 7995, 18 January 2024

<https://www.nature.com/nature/volumes/625/issues/7995>

[New issue; No digest content identified]

### **Nature Biotechnology**

Volume 42 Issue 1, January 2024

<https://www.nature.com/nbt/volumes/42/issues/1>

*Editorial* 08 Jan 2024

#### **[Tearing up the traditional biotech playbook](#)**

Bigger and more expensive science requires more extensive collaboration and new funding opportunities.

*News Feature*

## [Reducing the costs of blockbuster gene and cell therapies in the Global South](#)

Ben Johnson

Researchers in low- and middle-income countries are developing their own IP, scaling up local manufacturing, and looking for biomarkers — all in the hope of bringing costs down and getting therapies to people who need them.

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 20 Jan 2024)

[No new digest content identified]

### **Nature Genetics**

Volume 56 Issue 1, January 2024

<https://www.nature.com/ng/volumes/56/issues/1>

*Editorial* 02 Jan 2024

#### [A call for spatial omics submissions](#)

The field of spatial omics is developing rapidly, with a potentially transformative effect across many areas of biology. Nature Genetics invites authors to submit papers that use these techniques to answer questions of broad interest to researchers working in genetics and genomics.

### **Nature Human Behaviour**

Volume 7 Issue 12, December 2023

<https://www.nature.com/nathumbehav/volumes/7/issues/12>

#### ***Moral reasoning in the brain***

[Reviewed earlier]

### **Nature Medicine**

Volume 29 Issue 12, December 2023

<https://www.nature.com/nm/volumes/29/issues/12>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 23 Issue 1, January 2024

<https://www.nature.com/nrd/volumes/23/issues/1>

*COMMENT* 29 November 2023

#### [A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics](#)

Current regulation of T cell receptor (TCR)-based therapeutics may require repeated testing of patients for specific HLA alleles as well as companion diagnostics development, despite the invariant nature of the HLA genotype and availability of robust clinical HLA tests. This increases the burden on patients and the organizations developing these products. We propose regulatory flexibility to facilitate the development of and access to TCR-based therapeutics.

By [Miriam Meyer](#), et al.

*Review Article* 29 Nov 2023

#### [Tailor made: the art of therapeutic mRNA design](#)

The recent success of mRNA vaccines has boosted the prospects for the development of a new class of designer medicines based on mRNA. This Review discusses the multiple design parameters that need to be carefully considered to create highly effective mRNA medicines.

Mihir Metkar, Christopher S. Pepin, Melissa J. Moore

### **Nature Reviews Genetics**

Volume 25 Issue 1, January 2024

<https://www.nature.com/nrg/volumes/25/issues/1>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 23 Issue 12, December 2023

<https://www.nature.com/nri/volumes/23/issues/12>

[Reviewed earlier]

### **New England Journal of Medicine**

January 18, 2024 Vol. 390 No. 3

<https://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

### **[Fundamentals of Medical Ethics: Responding to Medical Errors — Implementing the Modern Ethical Paradigm](#)**

T.H. Gallagher and A. Kachalia

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 20 Jan 2024]

[No new digest content identified]

### **Pediatrics**

Volume 153, Issue 1 January 2024

<https://publications.aap.org/pediatrics/issue/152/4>

[Reviewed earlier]

### **PharmacoEconomics**

Volume 41, Issue 12 December 2023

<https://link.springer.com/journal/40273/volumes-and-issues/41-12>

[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 20 Jan 2024)

[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 20 Jan 2024)

[No new digest content identified]

### **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 20 Jan 2024)

#### **[Perceptions toward Ebola vaccination and correlates of vaccine uptake among high-risk community members in North Kivu, Democratic Republic of the Congo](#)**

Shiromi M. Perera, Stephanie Chow Garbern, Eta Ngole Mbong, Monica K. Fleming, Rigobert Fraterne Muhayangabo, Arsene Baleke Ombeni, Shibani Kulkarni, Dieula Delissaint Tchoualeu, Ruth Kallay, Elizabeth Song, Jasmine Powell, Monique Gainey, Bailey Glenn, Ruffin Mitume Mutumwa, Stephane Hans Bateyi Mustafa, Giulia Earle-Richardson, Rena Fukunaga, Neetu Abad, Gnakub Norbert Soke, Dimitri Prybylski, David L. Fitter, Adam C. Levine, Reena H. Doshi

Research Article | published 18 Jan 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002566>

### **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 20 Jan 2024)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 20 Jan 2024)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 20 Jan 2024]

#### **[Child malaria vaccine uptake in Ghana: Factors influencing parents' willingness to allow vaccination of their children under five \(5\) years](#)**

Sulemana Ansumah Saaka, Kamaldeen Mohammed, Cornelius K. A. Pienaaah, Isaac Luginaah

Research Article | published 19 Jan 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0296934>

#### **[Global perspectives of determinants influencing HPV vaccine introduction and scale-up in low- and middle-income countries](#)**

Dominique Guillaume, Dur-e-Nayab Waheed, Meike Schleiff, Kirithini Kasi Muralidharan, Alex Vorsters, Rupali J. Limaye

Research Article | published 16 Jan 2024 PLOS ONE

<https://doi.org/10.1371/journal.pone.0291990>

Abstract

Achieving WHO cervical cancer elimination goals will necessitate efforts to increase HPV vaccine access and coverage in low-and-middle-income countries (LMICs). Although LMICs account for the majority of cervical cancer cases globally, scale-up of HPV vaccine programs and progress toward coverage targets in LMICs has been largely insufficient. Understanding the barriers and facilitators

that stakeholders face in the introduction and scale-up of HPV vaccination programs will be pivotal in ensuring that LMICs are equipped to optimize the implementation of HPV vaccination programs. This qualitative study interviewed 13 global stakeholders categorized as either academic partners or global immunization partners to ascertain perspectives regarding factors affecting the introduction and scale-up of HPV vaccination programs in LMICs. Global stakeholders were selected as their perspectives have not been as readily highlighted within the literature despite their key role in HPV vaccination programming. The results of this investigation identified upstream (e.g., financial considerations, vaccine prioritization, global supply, capacity and delivery, and vaccine accessibility, equity, and ethics) and downstream (e.g., vaccine acceptability and hesitancy, communications, advocacy, and social mobilization) determinants that impact program introduction and scale-up and confirmed that strong political commitment and governance are significant in garnering support for HPV vaccines. As LMICs introduce HPV vaccines into their national immunization programs and develop plans for scaling up vaccination efforts, strategic approaches to communications and advocacy will also be needed to successfully meet coverage targets.

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 20 Jan 2024]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

January 16, 2024 | vol. 121 | no. 3

<https://www.pnas.org/toc/pnas/121/3>

[Reviewed earlier]

### **PNAS Nexus**

Volume 2, Issue 12, December 2023

<https://academic.oup.com/pnasnexus/issue/2/12>

[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 38 - Issue 6 - December 2023

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 178 January 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/178/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

10 January 2024 Volume 291 Issue 2014

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]



## **Public Health**

Volume 226 Pages e1-e6, 1-274 (January 2024)

<https://www.sciencedirect.com/journal/public-health/vol/226/suppl/C>

*Review article Open access*

### **[Understanding vaccination hesitation among health professionals: a systematic review of qualitative studies](#)**

A. Prieto-Campo, A.D. Batista, T. Magalhães Silva, M.T. Herdeiro, ... M. Zapata-Cachafeiro

Pages 17-26

## **Public Health Ethics**

Volume 16, Issue 2, July 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

## **Public Health Genomics**

2023, Vol. 26, No. 1

<https://karger.com/phg/issue/26/1>

[Reviewed earlier]

## **Public Health Reports**

Volume 139 Issue 1, January/February 2024

<https://journals.sagepub.com/toc/phrg/139/1>

[Reviewed earlier]

## **Qualitative Health Research**

Volume 34 Issue 3, February 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

## **Research Ethics**

Volume 20 Issue 1, January 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 20 Jan 2024]

[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

16 Jan 2024

### **[Stratification of risk areas for measles transmission: a systematic review](#)**

*Review* | Portuguese |

## **Risk Analysis**

Volume 44, Issue 1 Pages: 1-280 January 2024  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>  
[Accessed 20 Jan 2024]  
[Reviewed earlier]

## **Science**

Volume 383| Issue 6680| 19 Jan 2024  
<https://www.science.org/toc/science/current>  
*Editorial*  
[Time to support Indigenous science](#)  
BY Robin Wall Kimmerer, Kyle A. Artelle  
18 Jan 2024

## **Science and Engineering Ethics**

Volume 29, Issue 6 December 2023  
<https://link.springer.com/journal/11948/volumes-and-issues/29-6>  
[Reviewed earlier]

## **Science Translational Medicine**

Volume 16| Issue 730| 17 Jan 2024  
<https://www.science.org/toc/stm/current>  
[New issue; No digest content identified]

## **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>  
[Accessed 20 Jan 2024]  
[No new digest content identified]

## **Social Science & Medicine**

Volume 339 December 2023  
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/339/suppl/C>  
[Reviewed earlier]

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>  
[Accessed 20 Jan 2024]  
[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 44, Issue 6 December 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-6>

[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 56 November–December 2023

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/56/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 29, Issue 1 Pages: i-iv, 1-71 January 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## **Vaccine**

Volume 42, Issue 2 Pages 65-402 (12 January 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/2>

[Reviewed earlier]

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 20 Jan 2024]

*Latest Articles [Selected]*

[No new digest content identified]

## **Value in Health**

January 2024 Volume 27 Issue 1 p1-132

[New issue; No digest content identified]

## **World Development**

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

[Reviewed earlier]



### ***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)



.....

## ***Pre-Print Servers***

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 20 Jan 2024]

*Selected Research*

[No new digest content identified]

### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 20 Jan 2024]

[Filter: All articles]

### **[Mapping the Existing Body of Knowledge on New and Repurposed TB Vaccine Implementation: A Scoping Review](#)**

Joeri Sumina Sumina Buis, Degu Jerene, Agnes Gebhard, Roel Bakker, Arman Majidulla, Andrew D. Kerkhoff, Rupali Limaye, Puck T Pelzer

medRxiv 2024.01.18.24301490; doi: <https://doi.org/10.1101/2024.01.18.24301490>

*Abstract*

There is global consensus on the urgent need for a safe and effective TB vaccine for adults and adolescents to improve global TB control, and encouragingly, several promising candidates have advanced to late-stage trials. Significant gaps remain in understanding the critical factors that will facilitate the successful implementation of new and repurposed TB vaccines in low- and middle-income countries (LMICs), once available. By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these adults and adolescent vaccines. This review explores four key dimensions: (1) epidemiological impact, (2) costing, cost-effectiveness, and/or economic impact, (3) acceptability, and the (4) feasibility of implementation; this includes implementation strategies of target populations, and health system capabilities. Results indicate that current research primarily consists of epidemiological and costing/cost-effectiveness/economic studies in India, China, and South Africa, mainly modelling with M72/AS01, BCG revaccination, and generic vaccines. Varying endpoints, vaccine efficacies, and vaccination coverages were used. Globally, new, and repurposed TB vaccines are estimated to save millions of lives. Economically, these vaccines also demonstrate promise with expected cost-effectiveness in most countries. Projected outcomes were dependent on vaccine characteristics, target population, implementation strategy, timing of roll out, TB burden/country context, and vaccination coverage. Potential barriers for vaccine acceptability included TB-related stigma, need for a second dose, and cost, while low pricing, community and civil society engagement and heightened public TB awareness were potential enablers in China, India, and South Africa...

### **[Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis](#)**

Camila Aparicio, Zachary I Willis, Mari M Nakamura, Joshua Wolf, Cordell Little, Gabriela M Maron, Paul K Sue, Brenda I Anosike, Christine Miller, Laura L Bio, Prachi Singh, Scott H James, Carlos R Oliveira, PIDS Pediatric COVID-19 Therapies Task Force

medRxiv 2024.01.17.24301452; doi: <https://doi.org/10.1101/2024.01.17.24301452>

### **[The Seasonal Influenza Vaccine Cannot Trigger a Titer Increase Among Some Elderly Individuals](#)**

Yang Ge, Wannan Cao, Shengzhi Sun, Ted M. Ross, Ye Shen

medRxiv 2024.01.17.24301451; doi: <https://doi.org/10.1101/2024.01.17.24301451>

**[Sex and gender differences in adverse events following receipt of influenza and COVID-19 vaccination among healthcare workers](#)**

Anna Yin, Nadia Wang, Patrick J Shea, Erica Rosser, Helen Kuo, Janna R Shapiro, Katherine ZJ Fenstermacher, Andrew Pekosz, Richard E Rothman, Sabra L Klein, Rosemary Morgan  
medRxiv 2024.01.17.24301440; doi: <https://doi.org/10.1101/2024.01.17.24301440>

**[Overall Health Effects of mRNA COVID-19 Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis](#)**

Stine S Hoffmann, Sebastian Nielsen, Sanne M. Thysen, Ram Duriseti, Christine Stabell Benn  
medRxiv 2023.12.07.23298573; doi: <https://doi.org/10.1101/2023.12.07.23298573> Revision

**[Predicting COVID-19 Infection Among Older Syrian Refugees in Lebanon: A Multi-Wave Survey](#)**

Berthe Abi Zeid, Tanya El Khoury, Sawsan R Abdulrahim, Hala Ghattas, Stephen J McCall  
medRxiv 2024.01.17.24301436; doi: <https://doi.org/10.1101/2024.01.17.24301436>

**[Factors contributing to immunization coverage among children less than 5 years in Nadowli-Kaleo District of Upper West Region, Ghana](#)**

Alice Kuuyi, Robert Kogi  
medRxiv 2024.01.17.24301424; doi: <https://doi.org/10.1101/2024.01.17.24301424>

**[Inequalities in ownership and availability of home-based vaccination records in 82 low- and middle-income countries](#)**

Bianca de Oliveira Cata-Preta, Andrea Wendt, Thiago Melo Santos, Luisa Arroyave, Tewodaj Mengistu, Daniel R Hogan, Aluisio JD Barros, Cesar Gomes Victora, M. Carolina Danovaro-Holliday  
medRxiv 2024.01.16.24301369; doi: <https://doi.org/10.1101/2024.01.16.24301369>

**[Utilizing Natural Language Processing and Large Language Models in the Diagnosis and Prediction of Infectious Diseases: A Systematic Review](#)**

Mahmud Omar Sr., Dana Brin Sr., Benjamin S Glicksberg Sr., eyal Klang Sr.  
medRxiv 2024.01.14.24301289; doi: <https://doi.org/10.1101/2024.01.14.24301289>

**[Understanding Low Vaccine Uptake in African, Caribbean, and Black Populations Relative to Public Health in High-Income Countries: A Scoping Review Protocol](#)**

Josephine Etowa, Sheryl Beauchamp, Victoria Cole  
medRxiv 2024.01.14.24301294; doi: <https://doi.org/10.1101/2024.01.14.24301294>

**[Assessing yellow fever outbreak potential and implications for vaccine strategy](#)**

Keith Fraser, Arran Hamlet, Kévin Jean, Daniel Garkauskas Ramos, Alessandro Romano, Jennifer Horton, Laurence Cibrelus, Neil Ferguson, Katy A.M. Gaythorpe  
medRxiv 2023.12.19.23300139; doi: <https://doi.org/10.1101/2023.12.19.23300139> Revision

**[Protection afforded by post-infection SARS-CoV-2 vaccine doses: a cohort study in Shanghai](#)**

Bo Zheng, Bronner Gonçalves, Pengfei Deng, Weibing Wang, Jie Tian, Xueyao Liang, Ye Yao, Caoyi Xue  
medRxiv 2024.01.09.24301069; doi: <https://doi.org/10.1101/2024.01.09.24301069> Revision

**OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

**We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.**

## Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 20 Jan 2024]

*Selected Research*

*Research Article Open Access*

**[REVISED-Healthcare resource allocation decisions and non-emergency treatments in the aftermath of Covid-19 pandemic. How should children with chronic illness feature in prioritisation processes?](#)** [version 2; peer review: 1 approved, 1 approved with reservations]

Sapfo Lignou, et al.

In the aftermath of the Coronavirus disease 2019 (Covid-19) pandemic, allocation of non-urgent medical interventions is a persistent ethical challenge as health systems currently face an unprecedented backlog of patients requiring treatment. Difficult decisions must be made that prioritise certain patients over others. Ethical resource allocation requires that the needs of all patients are considered properly, but at present there is no guidance that can help support such decision-making which explicitly considers the needs of children with chronic and complex conditions.

\* \* \* \*

## **Think Tanks**

**Brookings** [to 20 Jan 2024]

<http://www.brookings.edu/>

*Research*

**[The pandemic inflation episode is still unwinding](#)**

*No new digest content identified.*

**Center for Global Development** [to 20 Jan 2024]

<https://www.cgdev.org/>

*All Research [Selected]*

*Blog Post*

**[Vaccination Data Is Becoming Systematically Biased](#)**

Brian Webster et al.

January 09, 2024

**Chatham House** [to 20 Jan 2024]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 20 Jan 2024]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*  
*No new digest content identified.*

**CSIS** [to 20 Jan 2024]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 20 Jan 2024]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

**[More Children are Losing Medicaid Coverage as Child Poverty Grows](#)**

January 16, 2024 News Release

Children's Medicaid and Children's Health Insurance Program (CHIP) enrollment declined by 5.5%, or 2.3 million children, from March 2023, before the unwinding began, to September 2023, according to KFF's latest analysis. Across all 50 states and DC, at least 14,377,000 people were disenrolled from Medicaid between April 1 and January...

**McKinsey Global Institute** [to 20 Jan 2024]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 20 Jan 2024]

<https://odi.org/en/publications/>

*Publications [Selected]*

**[Humanitarian leadership: learning from the past and directions for the future](#)**

17 January 2024

Working papers

**Pew Research Center** [to 20 Jan 2024]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 20 Jan 2024]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*No new digest content identified.*

**Urban Institute** [to 20 Jan 2024]

<https://www.urban.org/publications>

**[New Research Publications - Selected](#)**

*Public Comment*

## [Hearing on Addressing Long COVID: Advancing Research and Improving Patient Care](#)

January 19, 2024

Improving the health and well-being of people with Long COVID requires a holistic and multidisciplinary approach, within and beyond the health care system. The Urban Institute submitted this letter to the US Senate Committee on Health, Education, Labor and Pensions for the record to share some of our recent survey findings on the prevalence of Long COVID and the economic and health challenges facing those who experience it. While we wait for research and clinical trials on Long COVID, which must be urgently prioritized, we must ensure that people have access to quality and affordable health care and their basic needs are met.

*Research Report*

## [The Sociopolitical Context of the Unequal Treatment Report: Then and Now](#)

January 17, 2024

... Efforts by health care researchers, funders, leaders, and policymakers to address inequities are influenced by the sociopolitical context within and outside health care. Contending with that context will facilitate enduring change...

**World Economic Forum** [to 20 Jan 2024]

<https://agenda.weforum.org/press/>

*Media [Selected]*

*News* 18 Jan 2024

## [Annual Meeting 2024: Rebuilding Trust Amid Uncertainty](#)

:: At a moment of growing fragmentation and polarization, the World Economic Forum's Annual Meeting 2024 served as a platform for advancing dialogue, cooperation and action-oriented partnership.

:: Nearly 3,000 leaders from government, business and civil society from more than 125 countries, including 350 heads of state and government, and ministers, participated in the meeting and connected across diverse viewpoints on key issues.

:: Participants advanced new ideas and initiatives to increase resilience and security, revive economic growth, protect the climate and nature, balance innovation and guardrails for technology, and invest in jobs, skills and health.

## [AI Governance Alliance Calls for Inclusive Access to Advanced Artificial Intelligence](#)

News 18 Jan 2024

## [Business and Faith-based Groups Partner to Support the World's Vulnerable](#)

News 17 Jan 2024

## [Reskilling Revolution Providing Over 600 Million People with Better Education, Skills and Job Opportunities by 2030](#)

News 17 Jan 2024

## [New Global Alliance for Women's Health Could Help Boost Global Economy by \\$1 Trillion Annually by 2040](#)

News 17 Jan 2024

-

.....

.....

**Public Consultations/Call for Inputs/Call for Papers**



## **Public consultation on antimicrobial manufacturing effluent guidance**

21 December 2023

**Deadline: 26 January 2024.**

### *Summary*

WHO is seeking public feedback on draft "WHO Guidance on waste and wastewater management in pharmaceutical manufacturing with emphasis on antibiotic production"

Antibiotics provide great value to humanity to prevent and treat infectious disease. However, environmental emission of antibiotics during manufacturing has potential to contribute to the emergence and spread of AMR. Therefore, there is a recognised need, stemming from a World Health Assembly resolution and the [Global Action Plan on AMR](#), for international evidence-based guidance and tools on the management of manufacturing waste containing antimicrobials to guide the target audiences of this document.

Public submitters can download the draft guidance and background documents below and provide comments in the [online feedback form](#) before 26 January 2024.

:: [WHO Guidance on waste and wastewater management in pharmaceutical manufacturing with emphasis on antibiotic production](#)

:: [Background document on derivation of PNECs for resistance selection](#)

## **Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline (PDF/177.49 KB)**

EMA

First published: 31/10/2023 **Consultation dates: 01/11/2023 to 30/01/2024**

### *Summary/Problem statement [Excerpt]*

The proposed guideline will replace Guideline on influenza vaccines, non-clinical and clinical modules (EMA/CHMP/VWP/457259/2014).

...The current guideline text addresses collection of vaccine effectiveness data for approved vaccines by season. The collection of reliable data, especially brand-specific data, has proven difficult even within countries with high quality influenza disease surveillance. There is a need to rediscuss the feasibility of the current recommendations, while still acknowledging the utility of such data to detect unexpected effectiveness signals.

Overall, there is some degree of urgency to revise the guideline on non-clinical and clinical development of influenza vaccines. In particular, to add sections relevant to the development of mRNA-based influenza vaccines and to reflect on how lessons learned from the COVID-19 pandemic could be relevant to the development of influenza vaccines, including those intended only for pandemic usage.

Comments should be provided using this [EUSurvey form](#). For any technical issues, please contact the [EUSurvey Support](#)

## **Declaration of Helsinki – Phase I Public Comment Period**

World Medical Association

In order to maximize input by all stakeholders and the public, we are providing two separate public comment periods. A phase 1 public comment period is being held now to address issues from the first few regional meetings, and a phase 2 comment period will follow in the spring when additional topics have been addressed.

*Open Now: Phase 1 Public Comment Period Due: 7 February 2024.*

The workgroup's proposed edits to date are now available for public comment. To submit your or your organization's feedback, download the [phase 1 public comment document](#)

**Call for Papers: Establishing the impact of WHO’s normative and standard-setting functions: a call for papers**

WHO - Bull World Health Organ. 2023 Oct 1; 101(10): 618–618A. Published online 2023 Oct 1.

**The deadline for submissions is 1 March 2024**

*Editorial*

Lisa M Askie<sup>a</sup>, Rebekah AL Thomas<sup>a</sup>, Rok Ho Kim<sup>a</sup>, Mubashar Sheikh<sup>a</sup>, Jeremy Farrar<sup>b</sup>

doi: 10.2471/BLT.23.290829 PMID: PMC10523809

Normative leadership is a core function of the World Health Organization’s (WHO) mandate, as outlined in its founding principles.<sup>1</sup> This leadership role is realized by developing evidence-based and ethically sound guidelines as well as other normative products that guide Member States in their public health decisions and actions, and by ensuring their recommendations are implemented.<sup>2</sup> WHO exercises its capacity for normative leadership to influence the development of legal norms and health policy and practice within its Member States...

... In the past five years, WHO has initiated a major change process, driven by its current Thirteenth Global Programme of Work,<sup>3</sup> the transformation agenda, and the need to respond to major global events including the coronavirus disease 2019 (COVID-19) pandemic and other crises. More recently, WHO has developed a comprehensive strategy to enhance its capacities and capabilities at country level, to ensure that its normative work drives measurable impact for all people more effectively.

Despite these initiatives, to date it is unclear whether these changes have improved WHO’s credibility and impact as a normative organization. Questions remain as to how successful WHO’s normative leadership role has been, how it can be further strengthened and how the impact of WHO’s work in countries should be measured and rated in the future. The recent COVID-19 pandemic exposed both the strengths of and the challenges to WHO’s normative leadership and global reach. While realizing the crucial role of WHO as a key directing and coordinating authority, the global health community has also witnessed the unprecedented rise of misinformation and mistrust in science.

Considering the spotlight on WHO’s global normative leadership role during the pandemic,<sup>4</sup> and looking to prepare for future threats such as the health effects of climate change and ongoing conflict situations, the Bulletin of the World Health Organization calls for papers to help shape and inform WHO’s mandate going forward. Topics of interest include: where has WHO succeeded in its normative leadership role? In what specific areas has it successfully shaped global health, and why were these initiatives successful? Where has WHO normative guidance been less impactful? If so, why was this the case, and what lessons can be learnt to improve impact in the future? What does the future of WHO’s normative function look like, particularly in the context of digital technology and artificial intelligence? What aspects of the Organization’s mandate, structure, function and administration need to be further strengthened or changed?

The Bulletin welcomes contributions from all stakeholders including public health decision-makers, researchers, and civil society and community representatives. Articles that propose innovative but feasible ways by which WHO can further strengthen its normative leadership and guidance role, are encouraged.

\* \* \* \* \*  
\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \* \*  
\* \* \* \* \*